HYB 262-05 reacts with malonyldialdehyde (MDA)-treated LDL but not with native LDL.
Immunogen
Low-density lipoprotein purified from human plasma and treated with MDA
Application
ELISA, WB
Species reactivity (positive)
Human
Species reactivity (negative)
Not determined
Subclass
IgG2b/l
Gene ID
4018
Clone number
10G10
Epitope
Not determined
Purification
Protein-A purified
Form
Liquid
Solvent
0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide
Storage
4-8ºC without exposure to light. No precautions necessary during handling.
Target
Low-density lipoprotein (LDL) is the carrier protein for cholesterol in the blood. LDL binds to its receptor on the capillary walls and thereby mediates the uptake and clearence of cholesterol from the circulation. In atherosclerotic lesions oxidatively modified LDL is found and oxidized LDL is specifically recognized and ingested by macrophages via scavenger receptor A and CD36. Oxidized LDL may be a marker of atherosclerosis but the precise changes in oxidized LDL are not well described. MDA-treated LDL appear to be different from LDL oxidized by other means.